공시 • Feb 19
Protagenic Therapeutics, Inc. announced delayed 10-Q filing On 02/18/2026, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Jan 16
Nasdaq Stock Market to Delist Common Stock of Protagenic Therapeutics, Inc The Nasdaq Stock Market announced that it will delist the common stock, and warrants of Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc.’s securities were suspended on January 5, 2026 and have not traded on Nasdaq since that time. 공시 • Jan 05
Protagenic Therapeutics Receives Delisting Notice from Nasdaq Beginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company") expects its common stock (PTIX") and warrants (PTIXW") to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC (Nasdaq") stating that trading of the Company's securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company's securities based on the Company's failure to satisfy Nasdaq continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders' equity) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). OTC trading is effected through registered broker-dealers, and quotation and trading information is generally available through brokerage platforms and publicly available quotation services. The Company intends to continue to file periodic and current reports with the SEC, which will be available on the SEC's EDGAR system. The OTC market may have different liquidity and trading characteristics than a national securities exchange. The Company is evaluating steps to regain compliance with Nasdaq listing requirements and to seek relisting on Nasdaq. The Company also intends to engage with market participants to facilitate the OTC transition and support liquidity in its securities. The Company has withdrawn its request for a hearing before a Nasdaq Hearings Panel and, accordingly, Nasdaq's determination is final. 공시 • Dec 08
Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025 Protagenic Therapeutics, Inc., Annual General Meeting, Dec 31, 2025. 공시 • Nov 27
Protagenic Therapeutics, Inc. Receives Notification Letter from Nasdaq Delisting Due to Non-Compliance with Listing Rules On November 20, 2025, Protagenic Therapeutics, Inc. received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2,500,000) and Nasdaq Listing Rule 5250(c)(1) (timely filing of periodic reports). As reported in the Company’s Transition Report on Form 10-QT for the period ended June 30, 2025, the Company’s stockholders’ equity no longer satisfies the minimum requirement of Rule 5550(b)(1). The Staff also cited the Company’s delated filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 as a separate basis for non-compliance under Rule 5250(c)(1). The Company is completing final steps for the Form 10-Q and expects to file it imminently. Because the Company had only recently regained compliance and remains subject to a mandatory one-year panel monitoring period under Nasdaq Listing Rule 5815(d)(4)(B), the Staff issued a determination to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. A timely hearing request will automatically stay any suspension of the Company’s securities for 15 calendar days. The Company will also request that the Panel a stay any suspension, pending the outcome of the hearing. During the automatic stay—and, if granted, during any extended stay—the Company’s common stock will continue to trade on The Nasdaq Capital Market. There can be no assurance that the Panel will grant the Company’s request for an extended stay or that the Company will regain compliance with Nasdaq’s continued listing standards. 공시 • Nov 15
Protagenic Therapeutics, Inc. announced delayed 10-Q filing On 11/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Aug 23
Protagenic Therapeutics Receives Notice of Non-Compliance from Nasdaq Due to Delayed Filing of Form 10-Q As disclosed in the Company’s Form 12b-25 filed on August 14, 2025, Protagenic Therapeutics, Inc. is finalizing merger-related consolidation of financial statements for the quarter ended June 30, 2025, including purchase accounting adjustments, pro forma financial information, and related disclosures. These procedures are being completed under Audit Committee oversight with the Company’s independent auditors and external advisors. The Company expects to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the ‘Form 10-Q’) in the near future. On August 20, 2025, the Company received a notice (the ‘Notification Letter’) from the Nasdaq Listing Qualifications department (‘Nasdaq’) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of the Form 10-Q. The notice does not immediately effect the listing or trading of the Company’s securities, which continue to trade on the Nasdaq Capital Market under the symbol ‘PTIX.’ The Company intends to submit a plan to regain compliance within 60 calendar days of the Notification Letter, and Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q’s due date. 공시 • Aug 15
Protagenic Therapeutics, Inc. announced delayed 10-Q filing On 08/14/2025, Protagenic Therapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. New Risk • Aug 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$2.46m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (US$2.46m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change).